cyrilzakka/clinical-trials huggingface dataset:
A Study on the Relationship Between Job Satisfaction and Retention Intentions of Emergency Room Nurses

Based on a survey conducted by the Nursing and Health Care Bureau of the Ministry of Health and Welfare in 2023, which investigated the recruitment and turnover rates of nursing personnel in 479 hospitals of different levels, the results revealed that the recruitment of nursing personnel was exceedingly challenging. The difficulty levels varied, with medical centers at 80%, regional hospitals at 67.9%, and district hospitals at 43.37%. Additionally, the turnover rates of nursing personnel were notably high, with medical centers at 10.21%, regional hospitals at 11.17%, and district hospitals at 14.52%. These rates all exceeded 10%, which means that, on average, one out of every ten nursing personnel resigned (Nursing and Health Care Bureau, Ministry of Health and Welfare, 2023).

This study aims to investigate the relationship between job satisfaction and retention intention among emergency room nursing personnel in a regional teaching hospital in Yunlin County. In the fiscal year 2023, the unit experienced an alarming turnover rate of approximately 82% among newly hired personnel. Therefore, the study intends to conduct further research and exploration into the job satisfaction and retention intention of emergency room nursing personnel.

The primary objectives of the research include examining the correlation between the demographic characteristics of emergency room nurses and their job satisfaction, the correlation between the demographic characteristics of emergency room nurses and their retention intention, and the correlation between job satisfaction and retention intention among emergency room nurses.

The study's subjects are nurses or nursing staff employed in the emergency department. The research is conducted through the distribution of questionnaires, and all responses are collected anonymously. The questionnaire is structured into three main sections: the first section covers demographic characteristics, the second section addresses job satisfaction items, and the third section focuses on retention intention items.

Upon collecting and encoding the data, the information will be compiled, and statistical analysis will be performed using Excel and SPSS version 25.0 statistical software to validate various research hypotheses.

The expected outcome of the study is a positive relationship between job satisfaction and retention intention among emergency room nurses, indicating that job satisfaction influences retention intention.


Eligibility Criteria:
Inclusion Criteria:

* Emergency Nurse
* Employed in an urgent care unit.
* Holds a nursing or registered nurse license.
* Currently engaged in nursing duties.
* Has a minimum of three months of nursing service in this hospital.

Exclusion Criteria:
A One Visit Follow Up of Adults With Fabry Disease Who Started Long-term Enzyme Replacement Therapy As Children

The objective of this study is to obtain follow up data on a cohort of well-studied patients with Fabry disease who have been on ERT since childhood for a total of about 15 years.

The long-term effect of initiating ERT in childhood is unknown. Prospective studies of Children with Fabry disease on 0.2 mg/kg agalsidase alfa every other week were performed. The patients were 7-17 years of age at initial study enrollment. The first open-label protocol was TKT023, a 6 months study (August 12, 2002-October 20, 2004) that was followed by an extension study TKT029 (June 10, 2004-June 15, 2011; ClinicalTrials.gov identifier NCT00084084). Since completing TKT029, all US patients were switched to commercial agalsidase beta. Therefore, these patients have now been treated for about 15 years.This study involves a one-visit follow up on these patients using the same protocol-driven studies as were used in TKT029. The long-term follow up data gathered will consist of a rare description of the disease profile in patients who were treated with ERT since childhood.

Eligibility Criteria:
Inclusion Criteria:

1. Patients who participated in TKT029 and who are willing and able to come to Dallas for 1 visit for standard of care testing.
2. Sign the protocol informed consent form
3. Have been on continuous commercial ERT since TKT029 has ended

Exclusion Criteria:

1. Patients who are unable to understand the nature, scope, and possible consequences of the study.
2. Patient does not give his written informed consent to participate in this study
3. Patient is unable to comply with the protocol, e.g., uncooperative with protocol schedule, refusal to agree to all of the study procedures.
4. Patient has been off ERT for an extended period of time as assessed by the investigator.
Brevera™ Breast Biopsy System Data Collection Study

The Brevera Breast Biopsy System integrates tissue acquisition, real time imaging, and post biopsy handling all during the same procedure. This post-market clinical trial will be performed to obtain clinical/operational data and feedback on the Brevera Breast Biopsy System.


Eligibility Criteria:
Inclusion Criteria:

* Female aged 18 years of age or older
* Subject has at least one breast imaging finding requiring biopsy for which images are available
* Subject is able to understand, read and sign the trial specific informed consent form after the nature of the trial has been fully explained to her

Exclusion Criteria:

* Patients who, based on the physician's judgment, may be at increased risk or develop complications associated with core removal or biopsy.
* Patients receiving anticoagulant therapy or may have bleeding disorders which may put the patient at increased risk of procedural complications based upon physicians judgment.
Development of a Virtual Reality Spatial Retraining Therapy to Improve Neglect in Stroke Survivors

Participants in this study will help test and develop a virtual reality (VR) system that is being designed to help people with spatial neglect after stroke.

Participants in this study will be tested to see if they have spatial neglect after their stroke, and the severity of such. Spatial neglect is a disorder that may occur after a stroke that leads to a person paying more attention to one side of their body over the other. Each testing session, they will perform paper and pencil neglect tests before and after playing a VR video game that is being designed as a potential future treatment. They will also give feedback on the game after the session is over. People who have spatial neglect after stroke are encouraged to apply.

Eligibility Criteria:
Inclusion Criteria:

* Read and speak English fluently
* Have a history of one stroke event that injured one cerebral hemisphere
* Presence of moderate to severe spatial neglect

Exclusion Criteria:

* History of progressive neurological disorders
* History of significant psychiatric disorders
* History of vestibular disorders
* Living outside a 50-mile radius of Kessler Foundation (located in West Orange, NJ)
Epidemiology of Helicobacter Pylori Infection in Children From Slovenia

The epidemiology of H. pylori infection among children in Slovenia has not been investigated. Therefore, we are conducting a study to examine the epidemiology of H. pylori and associated risk factors among children in Slovenia.

The population selection was from the three different geographic location in Slovenia. The selection of the studied places was based on their social and economic characteristics and medical provision. We included children from three age groups at the same time we collected information from the parents which may be important for H. pylori transmission.

Eligibility Criteria:
Inclusion Criteria:

* age 6, 14 and 17 years living in three different regions in Slovenia

Exclusion Criteria:

* none
The Gut Microbiome in Women With Polycystic Ovary Syndrome

Testing two different strategies for weight loss intervention and revealing possible changes in composition of gut microbiota, in order to provide more insight in the effect of dietary changes and weight loss treatments on gut microbiome in overweight and obese women with polycystic ovary syndrome (PCOS). The two strategies are:

* dietary advice plus myo-inositol and folic acid
* dietary advice plus liraglutide, glucagon-like peptide-1 (GLP-1) receptor agonist Primary outcome will be weight loss. Secondary outcomes are longitudinal changes in clinical features associated with PCOS and metabolic syndrome, longitudinal changes in gut microbiome with interventions.

Subjects will be treated during 16 weeks and follow-up will take 16 weeks after stop of treatment.


Eligibility Criteria:
Inclusion Criteria:

* PCOS according to ROtterdam criteria
* BMI ≥ 27 kg/m2 and at risk of metabolic syndrome or BMI ≥ 30 kg/m2

Exclusion Criteria:

* pregnancy
* pancreatitis (in the past)
* oral contraceptive pill use
* inflammatory bowel disease
* auto-immune disease
* immuno-modulatory drugs
* antidiabetic drugs
* anti-inflammatory drugs
The HEALiX™ Intubated Patient (IP) Pilot Study

The current standard of care for limiting the movement of mechanically ventilated critical care patients is the use of physical wrist restraints, which are both ineffective in preventing removal of invasive and adjunct respiratory support devices and have a multitude of negative physical and psychological consequences for the patient. The objective of the proposed research is to test an innovative device designed to allow more freedom of movement of mechanically ventilated patients without bending of the arms, thereby preventing removal of adjunct mechanical ventilation devices and invasive monitoring equipment.


Eligibility Criteria:
Inclusion Criteria:

* speak English
* legally authorized representative must speak English
* admitted by one of the services presiding over the selected intensive care units
* mechanically ventilated receiving analgesic-sedating medications
* have soft wrist restraints applied as part of their care plan documented in the medical record to reduce the risk of unplanned removal of medical devices

Exclusion Criteria:

* pregnant women
* prisoners
* patients who are in a medically induced coma or in a comatose state (Glasgow Coma Scale \<8) for any reason
Health Benefits of Alpine Skiing for the Elderly

Older people tend to live a sedentary lifestyle which causes a loss of cardiorespiratory fitness, impaired postural stability and a increased risk of falls. Social isolation of older people leads to depression and other mental diseases. However, numerous studies show that age-related degradation processes and functional limitations can be counteracted by physical activity. Various studies show that alpine skiing is a complex sport that places demands on the cardiorespiratory, neuromuscular and sensorimotor systems. With studies providing evidence to suggest alpine skiing is an appropriate activity for elderly as a health-enhancing sport, perhaps Alpine skiing could provide the physical activity needed to counteract age-related degradation processes and loss of function. To date, there is a lack of long-term intervention studies devoted to this topic. The aim of this study was to monitor the long-term effects of skiing on the health of older people, as to age-related muscle breakdown, cardiorespiratory fitness, body stability, general mobility and the overall psychological state of the subjects.


Eligibility Criteria:
Inclusion Criteria:

* Age 60-75 years of age at
* average or above average skiing ability
* average physical activity level
* willingness to ski regularly (2-3 days per week) for 12 weeks
* ability to give written informed consent

Exclusion Criteria:

* serious health problems that would make alpine skiing unjustifiable
Neural Mechanisms of Immersive Virtual Reality in Chronic Pain

This project examines, in chronic pain, the mechanisms of immersive virtual reality compared to the mechanisms of placebo hypoalgesia. The potential of developing new non-pharmacological premises for low-risk interventions for pain management is high.

Virtual reality (VR) has been seen as an intervention for alleviating clinical chronic (and acute) pain. An approach to pain management utilizing VR presents opportunities for reducing pain and suffering by using immersive, aesthetic, and multisensory stimulation. Investigator will analyze the behavioral and neural mechanisms of active VR against sham VR as two methods that investigate descending pain modulation. Thus, the central hypothesis is that those who respond to placebos will likely respond to active VR. If VR-induced analgesia depends upon the release of endogenous opioids.

In this project, the investigators will determine the effects of VR at the neural and clinical levels directly for TMD participants, inviting participants from an existing Colloca Lab-based cohort phenotyped for diagnosis, grade, and low/high impact pain profiles and prospective TMD participants in collaboration with Johns Hopkins University. These participants have agreed to be recontacted for further research. Investigator will determine the role of the opioid tone (AIM1). In Aim 1, the investigators will determine the role of the endogenous opioid tone for VR-induced hypoalgesia in TMD participants using VR, tonic painful stimuli, and naloxone given intranasally with established mu-opioid receptor occupancy to determine how the opioid tone shapes VR-induced hypoalgesia.

Eligibility Criteria:
Inclusion Criteria:

* Age (18-88 years)
* English speaker (written and spoken)
* Temporal Mandibular Disorder (TMD) for at least 3 months

Exclusion Criteria:

* Present or past degenerative neuromuscular disease
* Cardiovascular, neurological diseases, pulmonary abnormalities, kidney disease, liver disease, history of cancer within past 3 years
* Cervical pain other than TMD related (e.g. stenosis, radiculopathy)
* Any personal (or family first degree) history of mania, schizophrenia, or other psychoses
* Severe psychiatric condition (e.g., schizophrenia, bipolar disorders, autism) leading to hospitalization within the last 3 years.
* Use of antidepressants, ADHD medication, non-over-the-counter painkillers, methadone, benzodiazepines, barbiturates, and/or narcotics during the past 3 months
* Lifetime alcohol/drug dependence or alcohol/drug abuse in the past 3 months
* Pregnancy or breastfeeding
* Color-blindness
* Pain in jaw or temple in last 3 months due to toothache or infection
* Any facial trauma that has occurred in the last 6 weeks
* History of severe facial trauma in the last 3 months
* Impaired or uncorrected hearing
* Conditions that would interfere with the VR mask placement (e.g. trauma, burn, infection)
* Known history of severe motion sickness
* High blood pressure or symptomatic low blood pressure
* History of fainting
* History of angioedema
* Failed drug test (testing for opiates, cocaine, methamphetamines, amphetamines, and THC)
A Double-Blind, Randomized, Comparative Study of Delavirdine Mesylate (U-90152S) in Combination With Didanosine (ddI) Versus ddI Alone in HIV-1 Infected Individuals With CD4 Counts of <= 300/mm3

To evaluate the safety, tolerance, pharmacokinetics, and efficacy of delavirdine mesylate (U-90152S) in combination with didanosine (ddI) versus ddI alone in HIV-positive patients.


Eligibility Criteria:
Inclusion Criteria

Concurrent Medication:

Allowed:

* AZT.

Patients must have:

* HIV-1 seropositivity.
* CD4 count \<= 300 cells/mm3.
* No active or acute (onset within the past month) opportunistic infections such as active cryptococcosis, pneumocystis carinii, herpes zoster, histoplasmosis, or cytomegalovirus (CMV).
* Consent of parent or guardian if less than 18 years of age.
* Understanding of potential risk to fetus related to study participation.
* Acceptable medical history, physical exam, EKG, and chest x-ray during screening.

NOTE:

* Patients with cutaneous Kaposi's sarcoma requiring no systemic therapy are permitted.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

* Active tuberculosis that is sensitive to rifampin.
* Inability to swallow numerous tablets.
* Clinically significant active or acute medical problems, including progressive multifocal leukoencephalopathy, lymphoma, or malignancy requiring systemic therapy.
* Clinically significant hypersensitivity to piperazine-type drugs (e.g., Antepar and Stelazine).
* Grade 2 or worse baseline organ function. NOTE:
* Hemophiliacs with grade 2 bilirubin, alkaline phosphatase, SGOT, or SGPT will be considered if these values have been stable over the past year. NOTE:
* Patients with suspected Gilbert's syndrome will be considered if bilirubin is grade 2 or better.

Patients with the following prior conditions are excluded:

* History of pancreatitis within the past 2 years.
* History of clinically significant nervous system or muscle disease, seizure disorder, AIDS dementia, or psychiatric disorder that would preclude study compliance.
* History of grade 2 or worse peripheral neuropathy.
* Intolerance to ddI in previous treated patients.

Prior Medication:

Excluded:

* More than 4 months total of prior ddI.
* Any prior ddC, d4T, or 3TC.
* Prior nonnucleoside reverse transcriptase inhibitors, including L-drugs, nevirapine, TIBO, HEPT, delavirdine, atevirdine, and alpha-APA.
* Other investigational antiretroviral medications (including foscarnet) or immunomodulators (including all interferons) within 21 days prior to initial study drug dose.
* Prior prophylactic or therapeutic HIV-1 gp120 or 160 vaccines.
* Rifampin, rifabutin, astemizole, loratadine, or terfenadine within 21 days prior to initial study drug dose.
* Any unapproved investigational medication for any indication within 21 days prior to initial study drug dose.

Required:

* AZT therapy at some time prior to screening. Active substance abuse.
Infertility Markers in Serum, Urine, and Follicular Fluid

This study is only collecting specimens from current patients of PENN Fertility Care.

The purpose of this investigation is to assess if markers of oxidative stress that are known to be associated with other medical conditions can be detected in women undergoing infertility treatment and normal women of similar age. Oxidative stress may affect a woman's eggs or the follicular cells that surround and nurture them. Other markers of to be investigated include markers of cellular aging and DNA structural changes.

Presence of these markers will be compared in blood and urine samples taken during infertility treatment, and follicular fluid at the time of IVF (if applicable).


Eligibility Criteria:
Inclusion Criteria:

* Women aged 18-50
* Infertility patients only:

  1. Women undergoing infertility treatment (with or without in-vitro fertilization) at the University of Pennsylvania's PENN Fertility Care
  2. Verified infertility diagnosis of any of the following:

     * Endometriosis (minimal or mild)
     * Endometriosis (moderate or severe)
     * Tubal factor
     * Hypogonadotrophic hypogonadism
     * Polycystic ovary syndrome
     * Diminished ovarian reserve
     * Male factor
     * Unexplained
* Healthy normal volunteers only:

  1. Not undergoing infertility treatment
  2. Not using hormonal contraception

Exclusion Criteria:

* Currently pregnant or breastfeeding
* Post-menopausal
* Concurrent participation in investigational trial
* Other health problems which, in the opinion of the investigator, may affect participation
Effect of Vestibular Rehabilitation - a Randomized Controlled Trial

The aim of this study is to assess if early supported vestibular rehabilitation can reduce dizziness and improve daily life activities in patients with acute vestibular injury.

The study question is: Does early supported vestibular rehabilitation have an additional effect on dizziness symptoms and daily life functions compared to standard treatment?


Eligibility Criteria:
Inclusion Criteria:

* acute symptoms of dizziness, nausea and nystagmus
* diagnosed by videonystagmography (at least 25% reduced caloric response in one ear)
* age 18-70 years
* inclusion within one week after symptom debut

Exclusion Criteria:

* chronic dizziness
* psychiatric diagnosis that might interfere with participation
Comparison of Prosthetic Knee Performance During Sitting and Standing

The Ossur Prosthetic Power Knee claims to assist in helping people with transfemoral amputation to walk up stairs and stand up from sitting. We expect to find that this product has the ability to help unload the sound knee during these tasks. We plan to collect force and motion data while people stand up from a chair. We will compare the data from people using several types of prosthetic knees, including the power knee as well as from people who are not amputees to see what the force and motion contributions are from the different knees evaluated.


Eligibility Criteria:
Inclusion Criteria:

* 7 control subjects with normal lower extremity function: mentally independent adults with intact extremities. These individuals shall have no significant medical history that would impair their ability to perform 3, repeated, sit to stand trials. Exclusionary examples might include history positive for total joint arthroplasty of the hip or knee and significant cardiomyopathy. Control subjects will be non-amputee, generally healthy individuals, mentally capable of providing informed consent. They will have no significant medical history that could be perceived by investigators to hinder the ability to transfer. Anyone not meeting these criteria cannot be a control subject.
* 28 subjects with unilateral amputation at the level of the thigh. 7 each in four groups:

  1. Active Extension Group: Power Knee
  2. Microprocessor Stance Control Group: C-Leg, Rheo, Adaptive
  3. Non-Microprocessor Stance Control Group: Mauch, Catech or other stance control units
  4. Non-Microprocessor and Non-Stance Control units: WASB, polycentrics, pneumatics Each subject must have a prosthesis for which they have had for a minimum of 90 days in its present condition.
* All subjects must be:

  1. at least 21 years of age,
  2. mentally independent, and
  3. able to give informed consent.

Exclusion Criteria:

* Subjects are not candidates if they:

  1. are under 21 years of age
  2. are mentally dependent and unable to provide their own informed consent
  3. have worn the present prosthesis for less than 90 days in the current condition
  4. have bilateral amputation
* Subjects with an amputation are not candidates if they only use a prosthesis for transfers or therapy (K0 or K1 Medicare functional class). They must be independently ambulatory, at some level in the community (Medicare functional class "K2-K4"). They are furthermore not a candidate for this study if they have bilateral amputation (at any level) of the lower extremity as the purpose is to determine sound versus involved side loading, then against control. If all of the latter criteria are satisfied, the final piece is the 90 day prosthetic accommodation period. Candidacy then hinges upon the fact that they are accommodated to their current prosthesis as evident by having worn the current device, unaltered for the 90 days prior to testing.